Singapore, May 13 -- GSK plc has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to accelerate bepirovirsen in mainland China at launch.

Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B (CHB) under priority regulatory review in China. CTTQ is a market leader in hepatitis B in China with one of the country's most comprehensive liver disease portfolios and a broad commercial footprint covering more than 5,000 medical centres across care settings. CTTQ has played a significant role in advancing the diagnosis and treatment of hepatitis B in China.

The collaboration combines GSK innovation with CTTQ's l...